Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
MOORE TIMOTHY L. reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Timothy L. Moore received a grant of 8,170 shares of restricted common stock. The award was made at a stated price of $0.0000 per share and was granted under the BioLife Solutions 2023 Performance Incentive Plan.
According to the filing, these restricted shares will fully vest on the first anniversary of the vesting date of January 2, 2026. After this grant, Moore directly holds a total of 44,943 shares of BioLife Solutions common stock.
BioLife Solutions executive Karen A. Foster reported equity compensation activity involving company common stock. She acquired 32,112 shares at no cost as a grant under the BioLife Solutions 2023 Omnibus Performance Incentive Plan. The restricted stock vested at approximately 156% of the target amount based on total shareholder return versus selected peers for the period from January 1, 2024 through December 31, 2025. In a related tax-withholding disposition, 13,013 shares were withheld at a price of $22.65 per share to cover tax obligations upon vesting. After these transactions, she directly held 211,083 shares of common stock.
GOSWAMI JOYDEEP reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Joydeep Goswami received a grant of 8,170 shares of restricted common stock, recorded at a price of $0 per share as a stock award rather than a market purchase. Following this grant, his directly held common stock increased to 53,156 shares.
The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the disclosure, will fully vest on the first anniversary of the vesting date of January 2, 2026.
BioLife Solutions, Inc. filed its annual report describing a focused life sciences business supplying bioproduction tools for the cell and gene therapy industry. The company develops and manufactures biopreservation media, human platelet lysate, closed-system containers, and automated thawing and cell-processing devices used across CGT workflows.
BioLife has reshaped its portfolio through several divestitures of freezer, cold-chain logistics, and shipping businesses, while acquiring the remaining 90% of PanTHERA CryoSolutions to add next‑generation cryopreservation technology. Revenue is concentrated in the United States, and a small number of customers and CryoStor products drive a large share of sales.
The report highlights extensive risk factors, including heavy competition, reliance on key customers and suppliers, potential product defects, evolving global regulations, cybersecurity and AI-related risks, and the possibility of goodwill and intangible asset impairments. Management also emphasizes its patent portfolio, cGMP manufacturing, quality systems, and efforts to retain specialized talent to support growth.
BioLife Solutions reported strong growth for 2025, driven by its cell processing tools for the CGT market. Revenue from continuing operations reached $96.2 million, up 29% from $74.6 million in 2024. Fourth quarter revenue was $24.8 million, a 20% increase from $20.7 million.
GAAP gross margin for 2025 was 65%, down from 67%, while non-GAAP adjusted gross margin was 66% versus 69% in 2024. The company posted a 2025 GAAP net loss from continuing operations of $12.1 million, but delivered non-GAAP adjusted net income of $6.3 million and adjusted EBITDA of $25.0 million, or 26% of revenue, up from $13.3 million, or 18%.
In October 2025, BioLife completed the sale of its evo subsidiary for $25.5 million in cash and ended the year with $120.2 million in cash, cash equivalents, and marketable securities. For 2026, it guides to revenue of $112.5–$115.0 million, implying 17%–20% growth, with gross margins in the mid‑60% range, full‑year GAAP net income, and continued expansion of adjusted EBITDA margin.
Invesco Ltd. has filed an amended Schedule 13G reporting a passive ownership stake in BioLife Solutions Inc. common stock. Invesco may be deemed to beneficially own 3,932,191 shares, representing 8.2% of the outstanding common stock, held of record by its advisory clients.
Invesco reports sole voting power over 3,607,451 shares and sole dispositive power over all 3,932,191 shares, with no shared voting or dispositive power. The filing identifies Invesco Advisers, Inc. and Invesco Capital Management LLC as relevant subsidiaries, and notes that no individual has more than a 5% economic interest.
Invesco certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of BioLife Solutions.
BioLife Solutions, Inc. furnished a current report to disclose that on January 12, 2026 it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1, and the company states that this revenue information and the exhibit are being furnished, not filed, so they are not subject to certain liability provisions and are not automatically incorporated into other securities law filings.
BioLife Solutions, Inc. reports that its Chief Quality and Operations Officer, Karen Foster, has decided to retire. She provided notice of her decision on January 8, 2026, and her retirement will be effective March 31, 2026. The company states that her decision to retire is not due to any disagreement with BioLife Solutions on operations, policies, or practices. The company also expresses appreciation for her service and extends best wishes for her retirement.
BioLife Solutions Chief Financial Officer Troy Wichterman reported selling 990 shares of common stock on 01/06/2026 at $25.59 per share. Following this sale, he beneficially owned 150,746 shares.
The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 to satisfy tax withholding obligations arising from the vesting of restricted stock, indicating it was linked to equity compensation rather than a discretionary open-market exit.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations Officer, reported a small automatic sale of company stock. On 01/06/2026, she sold 335 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, she beneficially owned 191,984 shares of common stock directly. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023 and was used to cover tax withholding obligations tied to the vesting of restricted stock.